J 2023

Unraveling adipose tissue proteomic landscapes in severe obesity: insights into metabolic complications and potential biomarkers

HRUŠKA, Pavel; Jan KUČERA; Daniela KURUCZOVÁ; Marek BUZGA; Matej PEKAŘ et al.

Základní údaje

Originální název

Unraveling adipose tissue proteomic landscapes in severe obesity: insights into metabolic complications and potential biomarkers

Autoři

HRUŠKA, Pavel; Jan KUČERA; Daniela KURUCZOVÁ; Marek BUZGA; Matej PEKAŘ ORCID; Pavol HOLECZY; David POTĚŠIL; Zbyněk ZDRÁHAL a Julie DOBROVOLNÁ

Vydání

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, UNITED STATES, AMER PHYSIOLOGICAL SOC, 2023, 0193-1849

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30105 Physiology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 4.200

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/23:00132473

Organizační jednotka

Lékařská fakulta

EID Scopus

Klíčová slova anglicky

obesity; proteomics; subcutaneous adipose tissue; type 2 diabetes; visceral adipose tissue

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 2. 11. 2024 21:22, Ing. Martina Blahová

Anotace

V originále

In this study, we aimed to comprehensively characterize the proteomic landscapes of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in patients with severe obesity, to establish their associations with clinical characteristics, and to identify potential serum protein biomarkers indicative of tissue-specific alterations or metabolic states. We conducted a cross-sectional analysis of 32 patients with severe obesity (16 males and 16 females) of Central European descent who underwent bariatric surgery. Clinical parameters and body composition were assessed using dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance, with 15 patients diagnosed with type 2 diabetes (T2D) and 17 with hypertension. Paired SAT and VAT samples, along with serum samples, were subjected to state-of-the-art proteomics liquid chromatography-mass spectrometry (LC-MS). Our analysis identified 7,284 proteins across SAT and VAT, with 1,249 differentially expressed proteins between the tissues and 1,206 proteins identified in serum. Correlation analyses between differential protein expression and clinical traits suggest a significant role of SAT in the pathogenesis of obesity and related metabolic complications. Specifically, the SAT proteomic profile revealed marked alterations in metabolic pathways and processes contributing to tissue fibrosis and inflammation. Although we do not establish a definitive causal relationship, it appears that VAT might respond to SAT metabolic dysfunction by potentially enhancing mitochondrial activity and expanding its capacity. However, when this adaptive response is exceeded, it could possibly contribute to insulin resistance (IR) and in some cases, it may be associated with the progression to T2D. Our findings provide critical insights into the molecular foundations of SAT and VAT in obesity and may inform the development of targeted therapeutic strategies. NEW & NOTEWORTHY This study provides insights into distinct proteomic profiles of subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and serum in patients with severe obesity and their associations with clinical traits and body composition. It underscores SAT's crucial role in obesity development and related complications, such as insulin resistance (IR) and type 2 diabetes (T2D). Our findings emphasize the importance of understanding the SAT and VAT balance in energy homeostasis, proteostasis, and the potential role of SAT capacity in the development of metabolic disorders.

Návaznosti

EF15_003/0000469, projekt VaV
Název: Cetocoen Plus
EF17_043/0009632, projekt VaV
Název: CETOCOEN Excellence
EF18_046/0015974, projekt VaV
Název: Modernizace České infrastruktury pro integrativní strukturní biologii
MUNI/A/1343/2022, interní kód MU
Název: Zátěže kardiovaskulárního systému od A po Z
Investor: Masarykova univerzita, Zátěže kardiovaskulárního systému od A po Z
857560, interní kód MU
(Kód CEP: EF17_043/0009632)
Název: CETOCOEN Excellence (Akronym: CETOCOEN Excellence)
Investor: Evropská unie, CETOCOEN Excellence, Spreading excellence and widening participation
90242, velká výzkumná infrastruktura
Název: CIISB III
90269, velká výzkumná infrastruktura
Název: RECETOX RI II

Přiložené soubory